Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification

BACKGROUND: The objective of CaLIPSO, a Phase 2b, randomized, double-blind, placebo-controlled clinical trial, is to test the hypothesis that myo-inositol hexaphosphate (SNF472) attenuates the progression of cardiovascular calcification in patients receiving maintenance haemodialysis. Here we report...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellasi, Antonio, Raggi, Paolo, Bover, Jordi, Bushinsky, David A, Chertow, Glenn M, Ketteler, Markus, Rodriguez, Mariano, Sinha, Smeeta, Salcedo, Carolina, Garg, Rekha, Gold, Alex, Perelló, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857813/
https://www.ncbi.nlm.nih.gov/pubmed/33564440
http://dx.doi.org/10.1093/ckj/sfz144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857813/
https://www.ncbi.nlm.nih.gov/pubmed/33564440
http://dx.doi.org/10.1093/ckj/sfz144

Ejemplares similares